Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
71.63
+0.09 (0.13%)
Dec 5, 2025, 4:00 PM EST - Market closed
Avidity Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 20.87 | 10.9 | 9.56 | 9.22 | 9.33 | 6.79 | |
| Revenue Growth (YoY) | 106.27% | 13.98% | 3.64% | -1.09% | 37.41% | 192.67% | |
| Cost of Revenue | 488.19 | 303.59 | 190.97 | 150.4 | 101.18 | 37.6 | |
| Gross Profit | -467.32 | -292.7 | -181.41 | -141.18 | -91.86 | -30.82 | |
| Selling, General & Admin | 145.14 | 86.24 | 54.19 | 37.73 | 26.2 | 13.46 | |
| Operating Expenses | 145.14 | 86.24 | 54.19 | 37.73 | 26.2 | 13.46 | |
| Operating Income | -612.46 | -378.94 | -235.6 | -178.91 | -118.05 | -44.28 | |
| Interest Expense | - | - | - | - | - | -0.21 | |
| Interest & Investment Income | 63.93 | 56.88 | 23.97 | 4.98 | 0.1 | 0.21 | |
| Other Non Operating Income (Expenses) | -1.27 | -0.25 | -0.59 | -0.06 | -0.06 | -0.08 | |
| Pretax Income | -549.79 | -322.3 | -212.22 | -174 | -118.01 | -44.36 | |
| Net Income | -549.79 | -322.3 | -212.22 | -174 | -118.01 | -44.36 | |
| Net Income to Common | -549.79 | -322.3 | -212.22 | -174 | -118.01 | -44.36 | |
| Shares Outstanding (Basic) | 131 | 112 | 73 | 52 | 41 | 22 | |
| Shares Outstanding (Diluted) | 131 | 112 | 73 | 52 | 41 | 22 | |
| Shares Change (YoY) | 33.44% | 52.83% | 39.97% | 25.91% | 91.24% | 698.49% | |
| EPS (Basic) | -4.19 | -2.89 | -2.91 | -3.34 | -2.85 | -2.05 | |
| EPS (Diluted) | -4.19 | -2.89 | -2.91 | -3.34 | -2.85 | -2.05 | |
| Free Cash Flow | -592.26 | -307.94 | -123.29 | -139.09 | -98.55 | -38.21 | |
| Free Cash Flow Per Share | -4.51 | -2.76 | -1.69 | -2.67 | -2.38 | -1.76 | |
| Operating Margin | -2934.90% | -3477.43% | -2464.41% | -1939.65% | -1265.83% | -652.38% | |
| Profit Margin | -2634.59% | -2957.71% | -2219.87% | -1886.33% | -1265.38% | -653.53% | |
| Free Cash Flow Margin | -2838.14% | -2825.88% | -1289.66% | -1507.92% | -1056.76% | -562.97% | |
| EBITDA | -609.06 | -376.16 | -233.5 | -177.53 | -117.41 | -43.9 | |
| D&A For EBITDA | 3.39 | 2.78 | 2.1 | 1.39 | 0.64 | 0.37 | |
| EBIT | -612.46 | -378.94 | -235.6 | -178.91 | -118.05 | -44.28 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.